Introduction
============

COPD is a debilitating lung disorder that kills over 110 000 individuals each year, making it the fourth largest cause of death in the US. Multiple initiating events including inflammation, protease--antiprotease imbalance, and oxidant--antioxidant imbalance damage the parenchyma and airways, leading to tissue remodeling. An emerging hypothesis in the field is that subsequent changes in epithelial gene expression and cellular function result in permanent airway injury and destruction of lung matrix. Many of these events are mediated in part by MAP kinase signal transduction pathways. Five distinct MAP kinase pathways have been identified in eukaryotes. These cascades are activated by distinct stimuli (including cigarette smoke) and direct a variety of biological events. While it is unlikely that an individual signaling cascade mediates a disease with such complex pathologies, recent research efforts have greatly improved our understanding of the activation of MAP kinase pathways and how these pathways direct cellular responses in the lung of COPD patients.

A remarkable feature of these pathways is that different stimuli (environmental toxins, oxidants, steroid hormones, mitogens, UV light, heat shock, or changes in pH, osmolarity, and nutrient supply) can activate the same pathway, which impressively induces diverse cell behaviors through reversible phosphorylation of transcription factor targets. For example, although interleukin (IL)-8 expression typically occurs through p38, ERK1/2 and SAPK/JNK have recently been found to mediate increased expression of this cytokine (Brand et al 2005). Therefore, the "specificity" of MAP kinase signaling depends not only on the cellular environment, but also on the cell type involved. The diversity of stimuli and biological responses associated with MAP kinase signaling is detailed in [Table 1](#t1-copd-1-137){ref-type="table"}.

The classical MAP kinase cascade (Ras/ERK)
------------------------------------------

The best-characterized mammalian MAP kinase pathway is the Ras/ERK or classical MAP kinase pathway, composed of two genes with 90% sequence identity: ERK-1 (p44) and ERK-2 (p42) ([@b15-copd-1-137]). Additional ERK pathways include the less-often studied ERK-3 and ERK-5 cascades, which will not be reviewed here. Homologs for the ERK1/2 pathway are the pheromone-regulated kinases KSS1 and FUS3 in the yeast *Saccharomyces cerevisiae*, with similar modules in *Drosophila melanogaster* and *Caenorhabditis elegans* ([@b91-copd-1-137]). The phosphorylation substrate for ERK1/2 MAP kinases has a core motif with the short amino acid sequence serine/threonine-proline (S/T-P) ([@b23-copd-1-137]). The ERK1/2 MAP kinase pathway is typically activated, as the name suggests, by mitogenic stimuli, such as peptide growth factors EGF or PDGF ([Table 1](#t1-copd-1-137){ref-type="table"}). Binding of growth factor to its cell surface receptor tyrosine kinase leads to receptor dimerization and autophosphorylation. Phosphorylation of the intracellular domain of the receptor activates GEFs, such as sos, which are attached to the cytoplasmic receptor tail by adaptor molecules grb-2 or shc. GEFs facilitate the activation of the monomeric GTPase Ras, via exchange of GDP to GTP. Ras-GTP recruits and activates the serine--threonine MAP kinase kinase kinase kinase (MKKK) c-Raf at the membrane, leading to Raf-mediated phosphorylation of the dual-specificity MAP kinase kinase-1 and -2 (MKKs or MEKs), MEK1/2. Next, MEK1/2 phosphorylates threonine and tyrosine amino acid residues on MAP kinases ERK1/2. Active transit of ERK1/2 through the nuclear membrane pore allows ERK1/2 to phosphorylate a variety of transcription factors such as the TCF member ELK-1, mediating DNA binding and gene transcription. As a result of these molecular events cell proliferation usually occurs. For this reason the Ras/ERK pathway is best studied for its direct role in tumorigenesis. In vitro ([@b97-copd-1-137]), animal ([@b81-copd-1-137]), and human studies ([@b37-copd-1-137]) have shown correlations between cancer incidence and increased Ras activation, ERK1/2 activity, or DNA binding by ERK1/2 transcription factor targets. Activation of ERK1/2 is shown in [Figure 1](#f1-copd-1-137){ref-type="fig"}.

Studies of mice with targeted deletion of ERK genes have shown that ERKs are essential for normal development and survival. Erk1 knockout mice ([@b73-copd-1-137]) develop normally and are fertile, likely due to the compensatory function of ERK2, but demonstrate behavioral hyperactivity ([@b83-copd-1-137]) and a defect in T cell proliferation and differentiation ([@b73-copd-1-137]). Erk2 null mice die at embryonic day 6.5, prior to lung formation, with significant apoptosis occurring in all tissues, and impaired angiogenesis ([@b102-copd-1-137]). Erk5 null animals die at embryonic day 9.5--10.5 from impaired heart and vessel development (the heterozygous animals grow to adulthood normally and are fertile) ([@b78-copd-1-137]). These models demonstrate the role for ERKs during organogenesis, but conditional knockout animals are still needed to understand the role of ERKs in specific adult tissues and during adult-onset injury.

p38 MAP kinase cascades
-----------------------

The p38 MAP kinase family comprises four enzymes: p38α, p38β, p38γ, and p38δ. Early studies identified a 38 kDa protein that is tyrosine phosphorylated during lipopolysaccharide exposure or hyperosmolarity ([@b36-copd-1-137]). These enzymes have been studied for their ability to regulate TNF-α-induced inflammation ([@b59-copd-1-137]; [@b58-copd-1-137]). In particular, the p38 pathway is well characterized for its role in cytokine production in immune cells. This pathway can be activated not only by cellular stress such as osmotic shock, but also by growth factors, UV light, GPCR ligands, and hormones. Activation of p38 occurs through dual tyrosine phosphorylation on a motif (TGT) distinct from that of ERKs and SAPK/JNKs. The activation loops in which these tyrosines rest is 6 amino acids shorter than in the other MAP kinases. These differences suggest that the mechanism of phosphorylation of p38 is distinct from that for ERKs and JNKs. In addition, the upstream MKK3 is specific for p38 ([Table 1](#t1-copd-1-137){ref-type="table"}). Knockout mice have been generated for the p38α, p38β, and p38γ MAP kinases. Similar to the ERK5 null mice, the p38α null mice are embryonic lethal due to severe cardiac malformations, resulting from impaired placental angiogenesis ([@b1-copd-1-137]). There are no obvious phenotypes reported for the p38β and p38γ null mice ([@b54-copd-1-137]).

SAPK/JNK signaling
------------------

The SAPK/JNK pathway (p46, p54, and p55) is most notably involved in the control of apoptosis ([@b90-copd-1-137]). This pathway is activated by UV light, cell stress, TNF-α, IL-1, and osmotic shock, and typically targets the transcription factor c-Jun. Additional stimuli include inhibition of protein translation (which stresses the cell), growth factors, and shifts in temperature. Activation of this pathway leads to phosphorylation of several additional substrates, including those of the early-response proto-oncogene family c-fos, which leads to the formation of Jun-fos heterodimers or Jun homodimers to create the AP-1 transcription factor ([@b2-copd-1-137]). The binding activity of Jun is tightly controlled by phosphorylation of residues near the DNA-binding domain, but the role of the upstream SAPK/JNK molecules is not clear ([@b9-copd-1-137]).

The JNK proteins phosphorylate a variety of substrates, including paxillin and mitochondrial Bcl-2. Much information on the biological roles of JNK signaling was obtained from JNK null mice. Individual JNK1, JNK2, or JNK3 null mice are generally normal, but the compound (JNK1/JNK2) knockout animals exhibit serious defects, dying in utero due to neural tube malformation ([@b53-copd-1-137]). JNK3 is expressed in the nervous tissue and, interestingly, loss of JNK3 protects mice from kainic acid-induced neuronal death ([@b101-copd-1-137]; [@b52-copd-1-137]). The JNK1/JNK3 and the JNK2/JNK3 compound null animals appear normal ([@b53-copd-1-137]). JNK1 null mice have defective T cell proliferation and differentiation ([@b29-copd-1-137]), and CD4 T cells produce Th2 cytokines (IL-2, IL-4) in the absence of a Th2 stimulus ([@b29-copd-1-137]). Overall, targeted disruption of the JNK MAP kinase enzymes has revealed a great deal about their function during development. However, little is known about the specific role of these proteins in the adult lung.

Cigarette smoke and kinase activation in the lung
=================================================

Signal transduction cascades are generally initiated by diverse stimuli which activate transmembrane receptors such as receptor tyrosine kinases and G-protein coupled receptors ([Table 1](#t1-copd-1-137){ref-type="table"}). It is unclear whether cigarette smoke alters ligand-receptor interactions, or whether smoke can activate membrane-bound receptors directly. It is known, however, that smoke exposure is associated with rapid and persistent induction of several kinase pathways, typically within minutes. For example, our laboratory demonstrated rapid and lasting cigarette smoke-induced activation of ERK-1/2 MAP kinase in cultured SAECs ([@b67-copd-1-137]). We have also detected elevated pulmonary ERK-1/2 (p44/42) phosphorylation in mice exposed to cigarette smoke for 10 days ([@b67-copd-1-137]), which is in agreement with previous studies conducted in rats ([@b18-copd-1-137]). Most importantly, the relevance of these events to COPD was established by the discovery of significantly elevated ERK1/2 activity in airway and alveolar epithelial cells of patients with emphysema, compared with nonemphysematous controls ([@b67-copd-1-137]). [Figure 2](#f2-copd-1-137){ref-type="fig"} demonstrates the involvement of MAP kinase signaling in epithelial and inflammatory cell responses to cigarette smoke.

A central role for ERK1/2 in emphysema pathogenesis was established when our laboratory discovered that induction of MMP-1 by cigarette smoke in SAECs requires ERK1/2 MAP kinase signaling ([@b67-copd-1-137]). MMP-1 is an interstitial collagenase upregulated in emphysema ([@b84-copd-1-137]; [@b41-copd-1-137]), and generates structural and functional emphysema in transgenic mice ([@b25-copd-1-137]; [@b33-copd-1-137]). Indeed, polymorphisms in MMP-1 may play a role in lung function and COPD susceptibility ([@b46-copd-1-137]). Future work is needed to determine how ERK1/2 and MMP signaling persists even after the patient has stopped smoking ([@b67-copd-1-137]).

Analyses of baseline MAP kinase activity in AM of smokers and nonsmokers reveal, perhaps surprisingly, that smokers exhibit significantly *lower* active p38 levels than nonsmokers, and that there is no difference in the activity of ERK1/2 and SAPK/JNK kinases in AM between these two groups ([@b69-copd-1-137]). These data suggest that different lung cell types (epithelial and inflammatory cell) can activate different MAP kinase signaling pathways in response to smoke exposure. However, one must be cautious when interpreting studies of molecular signaling in lung tissue from smokers, since not all smokers will develop COPD.

In vitro studies of A549 cells and in vivo studies with rats demonstrate tobacco smoke-mediated induction of c-Fos, MEK1, and ERK2 MAP kinase activities ([@b18-copd-1-137]; [@b39-copd-1-137]). Activation of these signal transduction molecules can trigger pro-proliferative or pro-inflammatory transcription factors such as c-fos, c-myc, AP-1, and Elk-1 ([@b76-copd-1-137]), which translocate to the nucleus and enhance gene expression ([Figure 3](#f3-copd-1-137){ref-type="fig"}). One study reported increased mRNA and protein expression of Egr-1, an ERK1/2 substrate, in the lung tissue of patients with emphysema, suggesting that targets of ERK1/2 signaling are involved in pathogenesis ([@b106-copd-1-137]). It is also likely that activation of different MAP kinases induces the same transcription factor. For example, ERK1/2 ([@b19-copd-1-137]) and JNK pathways have each been shown to activate NFκB signaling in human monocytes and airway epithelial cells ([@b94-copd-1-137]), demonstrating the potential for crosstalk between these pathways.

Research examining the interactions between cigarette smoke and the plasma membrane of lung epithelial cells has identified a role for the EGF receptor in the initial activation of MAP kinase signaling. EGFR is activated by several ligands: EGF, TGF-α, epiregulin, and amphiregulin. Several groups have demonstrated direct phosphorylation of EGFR by tobacco smoke. [@b87-copd-1-137] identified rapid transcriptional and post-translational activation of EGFR by tobacco smoke in NCI-H292 bronchial epithelial cells (a pulmonary mucoepidermoid carcinoma cell line which constitutively expresses EGFR). [@b60-copd-1-137] later showed that EGFR activity was required for MUC5AC induction by smoke and elucidated the cytosolic events ([@b34-copd-1-137]). These investigations showed that smoke and reactive oxygen species induce MUC5AC gene expression through both 1) an EGFR-independent mechanism, in which reactive oxygen species traverse the membrane to activate JNK and 2) an EGFR-dependent pathway which activates ERK1/2. The two pathways converge in the nucleus, where respective transcription factor targets JunD and Fra-2 bind AP-1 sites in the distal region of the MUC5AC gene to increase transcription ([@b34-copd-1-137]). The role of EGFR in the activation of other genes in COPD has not been fully examined, and little is known about this process in primary epithelial cells of the small airways. [Figure 1](#f1-copd-1-137){ref-type="fig"} models the steps in the activation of ERK1/2 via EGFR activation by cigarette smoke.

Lung cell apoptosis and MAP kinase signaling
============================================

Apoptosis of several lung cell types has been detected in the lung tissue in COPD ([@b82-copd-1-137]; [@b4-copd-1-137]; [@b93-copd-1-137]; [@b103-copd-1-137]), and positively correlates with disease severity ([@b42-copd-1-137]). In general, apoptosis is associated with changes in p38 or JNK signaling. In lung fibroblasts apoptosis can occur as a result of an increased oxidant burden; however, the mechanism is unclear ([@b43-copd-1-137]). Recent data reveal that ceramide production in alveolar cells contributes to apoptosis and emphysema in mice ([@b74-copd-1-137]). No data on MAP kinase signaling exists in this model, but ceramide-induced apoptosis of A549 cells was recently shown to be mediated by JNK ([@b55-copd-1-137]), and ceramide-induced apoptosis resulting from cellular stress has been shown to require SAPK/JNK signaling ([@b96-copd-1-137]). Interestingly, ceramide can induce MMP-1 expression in dermal fibroblasts through ERK1/2- and p38-dependent mechanisms ([@b79-copd-1-137]). Data on primary lung epithelial cells are lacking.

Apoptosis in the lung tissue of animal models and patients with COPD may result from chronic exposure to irritants in smoke. Acrolein induces apoptosis of cultured bronchial epithelial cells ([@b71-copd-1-137]), and acrolein-induced cytotoxicity occurs via ERK1/2 in vascular smooth muscle cells ([@b77-copd-1-137]). Nicotine also has been shown to suppress apoptosis of neutrophils ([@b3-copd-1-137]), and is a potent inducer of ERK1/2 MAP kinase, with little effect on JNK or p38 pathways ([@b40-copd-1-137]). The complexity of these apoptosis-inducing events merits further research.

Cytokine stimulation of and by MAP kinase cascades
--------------------------------------------------

One result of smoke-induced MAP kinase signaling is increased gene transcription due to altered chromatin architecture. For example, there is an increase in the intrinsic histone acetyltransferase (HAT) activity of ATF-2 through phosphorylation by either JNK or p38 ([@b49-copd-1-137]). In addition, in vitro studies with A549 lung epithelial cells, for example, have demonstrated a cigarette smoke extract-mediated decrease in histone deactylase (HDAC) activity, contributing to unwinding of nuclear chromatin and cytokine gene expression ([@b70-copd-1-137]) ([Figure 3](#f3-copd-1-137){ref-type="fig"}). Similarly, HDAC activity inversely correlates with COPD severity, and its reduced activity is thought to contribute to disease pathogenesis via enhanced inflammatory cytokine production ([@b44-copd-1-137]). These regulatory mechanisms are not fully elucidated, but it is hypothesized that control of cytokine gene expression is regulated in part through histone modification.

Analyses of murine asthma models reveal that production of the Th2 cytokines IL-2, IL-13, and IFNγ in the airways (as represented by bronchoalveolar \[BAL\] fluid) is mediated via MAP kinase signaling, specifically ERK1/2 and JNK MAP kinases ([@b20-copd-1-137]). MAP kinases themselves may be activated by cytokines ([@b24-copd-1-137]; [@b66-copd-1-137]), but the effect depends upon the type of cytokine. For example, the proinflammatory Th1 cytokine IL-17 can induce ERK1/2, but not p38 or SAPK/JNK in A459 lung epithelial cells ([@b72-copd-1-137]). Mapping out these kinase-cytokine modules is complicated by the variety of cell types, signal crosstalk, and inflammatory mediators within the lung. Additional research into the role of MAP kinases in pulmonary cytokine expression and inflammation is needed.

Identifying the components of tobacco smoke that activate MAP kinases
---------------------------------------------------------------------

The most common and preventable cause of COPD is cigarette smoking ([@b64-copd-1-137]). Therefore, determining which pathways are activated in lung cells during tobacco smoke exposure is an important step towards identifying cellular mechanisms involved in the pathogenesis of COPD. However, an additional objective of research is to determine which components or fractions of the smoke (or tobacco leaf) are mediating such an effect. For example, several well-conducted studies have examined the roles of nicotine ([@b104-copd-1-137]; [@b7-copd-1-137]; [@b17-copd-1-137]; [@b105-copd-1-137]), cotinine ([@b17-copd-1-137]), acrolein ([@b10-copd-1-137]; [@b11-copd-1-137]; [@b71-copd-1-137]), acetaldehyde ([@b5-copd-1-137]; [@b80-copd-1-137]; [@b85-copd-1-137]; [@b68-copd-1-137]), and hydrogen peroxide ([@b80-copd-1-137]) in animals or cultured cells. It has been estimated that there are over 4700 chemicals in tobacco smoke ([@b70-copd-1-137]), making it difficult to identify specific tobacco component(s) responsible for smoking-induced MAP kinase activation ([Figure 3](#f3-copd-1-137){ref-type="fig"}). In addition, it is important to appreciate that in vivo ADME (absorption, distribution, metabolism, excretion) pharmacokinetics of combusted tobacco components cannot be predicted by in vitro studies of isolated components dissolved in dimethyl sulfoxide. Cell type-specific responses are also important, as demonstrated by studies showing that while oxidant-sensitive NFκB is activated by cigarette smoke extract in A549 cells ([@b70-copd-1-137]), no activation occurs in NHBE cells ([@b39-copd-1-137]).

Acrolein is a potent component of tobacco that has been shown to produce mucus metaplasia in the lungs of both mice ([@b11-copd-1-137]) and rats ([@b12-copd-1-137]). Acrolein also contributes to EGFR phosphorylation, MUC5AC transcription, and ERK1/2 activation in NCI-H292 airway epithelial cells ([@b26-copd-1-137]). In this cell culture system acrolein depleted glutathione (GSH) and increased the burden of oxidative stress, as is thought to occur in COPD. Acrolein also has been shown to inhibit apoptosis in neutrophils ([@b32-copd-1-137]), and activates all three MAP kinase pathways in smooth muscle cells ([@b77-copd-1-137]).

Nicotine is present naturally as an antimicrobial in tobacco leaves ([@b89-copd-1-137]), and is required for the addictive properties of cigarettes. Nicotine has been shown to increase normal branching morphogenesis and gene expression in embryonic mouse lung buds. However, the mechanisms involved are not known, and the response varies in different genetic strains ([@b100-copd-1-137]). In cultured human airway epithelial cells, nicotine has been shown to activate Ras, the MKKK in the classical ERK1/2 signaling pathway ([@b21-copd-1-137]; [@b35-copd-1-137]). In lung cancer cells nicotine has no effect on the activities of JNK and p38 MAP kinases, but does activate ERK2 ([@b40-copd-1-137]). It is thus reasonable that activation of the classical MAP kinase signaling pathway is one reason that nicotine is a potent anti-apoptotic agent in several different lung cell types ([@b3-copd-1-137]; [@b40-copd-1-137]).

Inhibitors of MAP kinase signaling
==================================

Cancer research stimulates broad interest in kinase inhibitors
--------------------------------------------------------------

MAP kinase inhibitors have been extensively studied in animal models of disease, particularly cancer. These efforts were driven in part by human studies revealing increased ERK phosphorylation or activity in tumor-derived lung tissue ([@b31-copd-1-137]; [@b37-copd-1-137]) or human lung cell lines ([@b97-copd-1-137]). Mouse models of lung cancer also demonstrate significant increases in several MAP kinase pathways ([@b99-copd-1-137]). Evidence from smoke-exposed mice, xenografted mice, or mice injected with the aggressive human A549 adenocarcinoma cells suggests that uncontrolled proliferation of lung cancer cells can be alleviated using kinase inhibitors, with subsequent improvements in lung structure ([@b51-copd-1-137]). Although these compounds were initially designed as cancer therapies, recent preliminary studies suggest that they may also possess significant benefit in treating emphysematous lesions and associated COPD pathologies (see below).

Potential for MAP kinase inhibitors as therapeutics in COPD
-----------------------------------------------------------

Inhibition of transcription factor activity can occur at the level of activation, translocation, or DNA binding. However, inhibition of the upstream kinases trumps the need to block nuclear transcription factors, by preventing the phosphorylation of these cytosolic DNA-binding effectors. Several inhibitors exist which have selective affinities for specific kinases, and which are, importantly, orally available ([Table 2](#t2-copd-1-137){ref-type="table"}). These drugs, which typically act in an ATP-competitive manner, have shown promise in their ability to block various COPD-relevant cellular behaviors in culture, such as protease production, mucus secretion, and cell proliferation. However, the side-effects of these drugs cannot be known until long-term animal studies are conducted. Impressively, the MAP kinase inhibitors currently used in humans demonstrate low incidences of side-effects. It is for this reason, perhaps, that protein kinases are postulated to be the primary drug targets of this century ([@b22-copd-1-137]).

Inhibitors of the classical MAP kinase pathway
----------------------------------------------

There are several points along the classical MAP kinase pathway that can be targeted for inhibition. At the membrane, inhibition can block receptor dimerization or the attachment of GEFs to the plasma membrane. Inhibitors of RTKs exist, such as EGFR inhibitors AG1478 and ZD1839 (gefitinib/ Iressa). ZD1839 has been shown to block lung injury in a mouse model of bleomycin-induced pulmonary fibrosis ([@b86-copd-1-137]), and to slow breast cell tumorigenesis in transgenic mice ([@b62-copd-1-137]). This drug has shown promise in clinical trials for lung cancer but adverse effects are often an issue ([@b92-copd-1-137]).

Compounds have also been designed to target the farnesylation of oncogenic Ras, thereby blocking its attachment to the plasma membrane ([@b22-copd-1-137]; [@b27-copd-1-137]). In addition, the cytoplasmic MEK inhibitors have been studied extensively for their ability to reduce or prevent the phosphorylation and activation of ERKs ([@b51-copd-1-137]). Indeed, MAP kinase inhibitors have been shown to be effective in cancer therapy in mouse models ([@b81-copd-1-137]).

PD98059 and UO126 are two of the few MAP kinase inhibitors that are not ATP competitive. While both have good specificity at inhibiting ERK1/2 activation (IC~50~ in the nm range), PD98059 has been shown to also inhibit cyclo-oxygenases 1 and 2, decreasing platelet aggregation ([@b14-copd-1-137]). PD98059 blocks the activation of MKK1 by binding to it and preventing its activation by Raf-1, but it does not act on active MKK1. While PD98059 has outstanding activity in vitro, the potential for in vivo toxicity limits its long-term use in animal models or humans ([@b22-copd-1-137]). One promising compound is CI-1040 (PD 184352), a specific small molecule inhibitor of MEK1/2. CI-1040 is well tolerated in humans and has shown efficacy as an anti-tumor agent ([@b51-copd-1-137]). Use of ERK inhibitors in animal models of smoke-induced emphysema has not been reported, but it is conceivable that this treatment would block the activation of ERK1/2, preventing the subsequent changes in gene expression.

p38 inhibitors
--------------

Inhibitors of p38 MAP kinase signaling have shown efficacy in ameliorating several COPD pathologies in animal models ([Table 2](#t2-copd-1-137){ref-type="table"}). These compounds were initially identified for their ability to prevent production of IL-1 and TNF from stimulated human monocytes ([@b59-copd-1-137]). The most popular p38 inhibitor used in basic science research applications is SB203580. Unfortunately, this compound has limited solubility and high toxicity and its use is generally restricted to cell culture assays ([@b22-copd-1-137]). But use in the laboratory can identify roles for p38 in disease. For example, as was shown for the MEK1/2 inhibitor PD98059, SB203580 can inhibit cyclo-oxygenases-1 and -2 ([@b14-copd-1-137]). These data demonstrate the importance of dose-response studies and careful analysis of the multiple pathways that may be affected by kinase inhibitors. SB203580 at 3--5 micromolar concentrations has been shown to block phosphorylation of phosphatidylinositol 3-kinase/protein kinase B (PKB)(Akt/Rac) kinase in IL-2 stimulated T cells ([@b56-copd-1-137]). The result is blockade of T cell proliferation via inhibition of cell cycle progression.

The efficacy of SB203580 on lung injury has also been tested in vivo ([@b6-copd-1-137]), with mixed results. Although researchers demonstrated an increase in p38 activity within neutrophils during acute lung injury, SB203580 did not decrease lung neutrophil influx or pulmonary edema during hemorrhage or lipopolysaccharide endotoxemia ([@b6-copd-1-137]). Similarly, the increased production of proinflammatory cytokines (MIP2, TNF-α) and activation of NF-κB in lung neutrophils induced in these models was not diminished by p38 inhibition.

Not all studies result in the same conclusions regarding the efficacy of p38 inhibitors. While the previous report did not demonstrate any benefit from p38 inhibition, others report positive outcomes. During synthesis of a different compound, SB239063, it was discovered that methylation of the nitrogen in the imidizole group greatly improved the drug's bioavailability ([@b61-copd-1-137]). The resulting inhibitor was shown to reduce myocardial infarction in the mouse ([@b47-copd-1-137]). In addition, use in rats and guinea pigs demonstrates that SB239063 effectively blocks p38 signaling in lung tissue when delivered intragrastrically before and after lipopolysaccharide inhalation challenge ([@b95-copd-1-137]), demonstrating that this compound has substrate efficacy in the lung. Most notably, this study showed that inhibition of p38 signaling with SB239063 could reduce pulmonary fibrosis, MMP-9 and IL-6 expression, and neutrophil influx in vivo ([@b95-copd-1-137]) ([Table 2](#t2-copd-1-137){ref-type="table"}). While the study by Arcaroli and colleagues demonstrated no benefit with SB203580, p38 inhibition with intratracheal SB239063 was much more effective. Taken together, these studies demonstrate that the benefit of p38 inhibition depends upon the type of inhibitor, delivery route, and disease model. The bioavailability of these compounds may be an important factor in their ability to control lung injury.

SAPK/JNK inhibitors
-------------------

Inhibitors of SAPK/JNK signaling have only recently become commercially available to basic scientists, and thus it will be some time before their effects on COPD-relevant events become clear. It has been demonstrated in several studies that this pathway is an important regulator of gene transcription, in part for the ability of JNKs (JNKs1, 2, and 3) to bind and phosphorylate the transcriptional regulator c-Jun. Inhibitors of this pathway have shown promise in controlling rheumatoid arthritis ([@b38-copd-1-137]). There are 13 upstream MKKKs which regulate JNK signaling (Science STKE JNK Pathway Connections Map 2002; URL: <http://stke.science-mag.org/cgi/cm/stkecm;CMP_10827>), suggesting that there are many targets for SAPK/JNK signaling blockade. As was shown for inhibitors of the classical MAP kinase pathway, SAPK/JNK inhibitors can also slow the growth of tumor cells in vivo ([@b30-copd-1-137]). Using the SP600125 compound, researchers demonstrated that JNK blockade reduced tumor growth in a mouse model of Lewis lung carcinoma ([@b30-copd-1-137]). This drug demonstrated anti-angiogenic as well as anti-proliferative effects ([@b30-copd-1-137]). SP600125 also reduces arthritis symptoms (inflammation, joint swelling) ([@b38-copd-1-137]) and several parameters of lipopolysaccharide-induced lung injury in rats ([@b57-copd-1-137]) ([Table 2](#t2-copd-1-137){ref-type="table"}). Other JNK inhibitors have shown promise in reducing neuronal apoptosis ([@b65-copd-1-137]) and pancreatic edema and inflammation ([@b98-copd-1-137]). The SAPK/ JNK pathway is also involved in T cell differentiation and activation ([@b28-copd-1-137]). Several studies have shown activated T cells in lung tissue and peripheral circulation of patients with COPD ([@b8-copd-1-137]), suggesting that inhibition of this MAP kinase cascade may impact on both central and peripheral inflammation in COPD. However, further studies are needed to define the precise roles of this pathway in the lung.

Pitfalls of kinase inhibition in COPD
-------------------------------------

A key objective in the design of therapeutics for COPD is to achieve significant functional and survival benefit for the patient. The first steps of kinase inhibition research involve a determination of the efficacy and toxicity of potential compounds. A major obstacle in the design of kinase inhibitors is obtaining high selectivity of the compound without side-effects. For example, MAP kinase blockade in embryonic mouse lung explants impairs branching morphogenesis and increases apoptosis ([@b50-copd-1-137]), which may translate into unwanted cellular and morphometric effects in adult lung tissue. Often, while a drug is able to inhibit the phosphorylation of its purified substrate in a test tube, it may not be biologically available, making it difficult to use for animal models of COPD, and ultimately humans. This has been shown to be the case for PD98059 and SB23580, two compounds that inhibit ERK1/2 and p38 kinases, respectively. Though cell permeable, these compounds demonstrate toxicity and solubility issues at higher concentrations which preclude their chronic use in animals, although short-term studies have been performed ([@b88-copd-1-137]; Kase et al 2005). In addition, because COPD patients typically present with several comorbidities, such as right-sided heart failure, muscle weakness, cachexia, and pulmonary vascular disease, the effects of drug therapy must be cautiously assessed.

Conclusions
===========

Transitioning COPD research
---------------------------

The molecular pathogenesis of COPD involves repeated smoke-induced injury to cells of the airways and parenchyma. These insults alter gene expression and epithelial cell function. Although diverse stimuli activate MAP kinase pathways in the lung, it is clear that tobacco smoke is an essential modifier of gene expression in COPD. Many cell processes are controlled by reversible phosphorylation of proteins. Analysis of the human genome revealed that the "kinome" (collection of all putative protein kinases) contains 518 genes, many with unknown function ([@b63-copd-1-137]). In vitro, animal, and human tissue studies of ERK1/2, SAPK/JNK, or p38 kinases have identified important roles for these enzymes in lung cell biology. Although individual MAP kinases have been shown to mediate specific COPD-relevant cellular events ([@b45-copd-1-137]), the crosstalk among these pathways within the lung milieu is complex ([@b75-copd-1-137]). Thus it is conceivable that even small reductions in kinase activity will result in robust reductions in gene transcription. Indeed, the use of MAP kinase inhibitors to reduce inflammation, apoptosis, cytokine production, and tissue injury has already been demonstrated. Currently, drug treatment strategies for COPD can be organized into several branches of target pathology ([Figure 4](#f4-copd-1-137){ref-type="fig"}). Although further studies are needed, the MAP kinase inhibitors, along with protease inhibitors and antioxidants, are beginning to emerge as promising therapeutic strategies for COPD.
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![The ERK1/2 pathway in airway epithelial cell responses to cigarette smoke. Cigarette smoke exposure has been shown to activate the EGFR in lung epithelial cells. Following dimerization and autophosphorylation of EGFR, a cascade of adaptor molecules and GTPases leads to the recruitment of Raf1 to the plasma membrane and its activation. Raf1 is a MAP kinase kinase kinase, which phosphorylates the MAP kinase kinase MEK1/2. MEK1/2 activation leads to phosphorylation of ERK1/2 MAP kinase, which can translocate to the nucleus and phosphorylate transcription factors which bind to regulatory elements in the promoters of target genes, inducing their expression. Transcription factors that are phosphorylated by ERK1/2 include Sp1, Ets1, AP-1, and ELK-1. Cigarette smoke-mediated activation of this cascade in lung epithelial cells is associated with hyperplasia, MMP-1 expression, MUC5AC expression, and release of EGF ligand. The list of transcription factors and cell responses is not comprehensive.](copd-1-137f1){#f1-copd-1-137}

![Cigarette smoke-induced MAP kinase activation and lung injury in COPD. The many chemicals, oxidants, and metabolites of cigarette smoke stimulate MAP kinase cascades within resident and inflammatory cells of the airways and parenchyma. Comparison of MAP kinase activities in the lung tissue of smokers, nonsmokers, and COPD patients has identified significant differences in these cascades. These signaling modules are linked to the indicated cellular processes, many of which are associated with COPD pathogenesis.](copd-1-137f2){#f2-copd-1-137}

![Transcriptional regulation by MAP kinases. Activated MAP kinases enter the nucleus and phosphorylate transcription factors such as Ets, AP-1, or ATF2. Transcription factor binding to cis-elements in the promoters of genes enhances transcription. Transcriptional control is also mediated via histone acetyltransferase (HAT) or histone deactylase (HDAC), which generally mediate activation or repression, respectively. Dashed lines indicate that kinase movement across the nuclear membrane occurs in both directions. Phosphorylation of transcription factors can also take place in the cytoplasm.](copd-1-137f3){#f3-copd-1-137}

![Model of the potential for MAP kinase inhibitors as COPD treatment strategies. COPD treatment branches are numerous, targeting the most destructive and debilitating processes, including airway inflammation, infection, exacerbations, and airway obstruction. Ongoing research to design drugs that reduce protease activity and oxidant injury will be critical in future COPD treatment. The potential for MAP kinase inhibitors is another promising area of research. These drugs have already demonstrated efficacy in reducing apoptosis, inflammation, cytokine production, fibrosis, and MMP expression. Future studies may result in the inclusion of MAP kinase inhibitors to COPD therapeutic strategies.](copd-1-137f4){#f4-copd-1-137}

###### 

Overview of the components of the ERK1/2, p38, and SAPK/JNK MAP kinase pathways

                                    MAPK pathway                                                                                                                                                                                         
  --------------------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  External stimuli                  EGF, NGF, PDGF, FGF, hormones, phorbol esters, insulin, neuropeptides, TGF-β                     TGF-β, FasL, LPS, IL-1β, LFA-1, hyperosmolarity, heat shock, cytokines, death stimuli, anisomycin   UV, γ radiation, insulin, FasL, LFA-1, cytokines, GFs, hyperosmolarity, oxidative stress
  Membrane receptor                 Gq-coupled R, RTKs, BCR, integrins, ion channels, TCR/CD3 complex, InsulinR                      GPCR, Fas/CD95, BCR                                                                                 RTKs, Fas/CD95, G12/13- coupled R, TNFR-2, DR3, BCR
  MAPKKK (ser/thr kinase)           Raf                                                                                              MLK3, TAK, DLK                                                                                      Mekk1,4, MLK3, ASK1
  MAPKK (dual specificity kinase)   MEK1/2                                                                                           MKK3/4/6                                                                                            MKK4/7
  MAPK                              ERK1/2                                                                                           p38                                                                                                 SAPK/JNK
  Transcription factors             Elk-1, Fra-1, TCF, ELK-1, Fos, Jun, AP-1, p90RSK, Ets, Smad2/3, Stat1/3, c-Myc, Pax6, *PPARγα*   ATF2, Elk-1, MEF-2C, CHOP, ETS1, STAT1, p53, Pax6, CREB, Fos                                        c-Jun, ATF2, Elk-1, p53, SMAD4, *NFAT4, STAT3*
  Other targets                     Synapsins, cPLA2, p70S6K, MNK, MAPKAPK2, *Bad, β-arrestin*                                       cPLA2, MAPKAPK2, HSP27, Tau, MNK                                                                    *IRS-1*, Bax
  Genes induced                     c-myc, c-fos, c-Jun, Bcl-2, CREB, Ets, Egr-1                                                     TNF-α, IL-1                                                                                         c-Jun, TGF-β, IFN, IL-2
  Biological events                 Proliferation, differentiation, growth                                                           Inflammation, apoptosis, cytokine- induced mRNA stability                                           Inflammation, apoptosis, survival

Text in italics indicates the factor is inhibited.

###### 

MAP kinase inhibitors and their effect in various models of tissue injury

  Pathway    Inhibitor   Effect                                                   Reference
  ---------- ----------- -------------------------------------------------------- ---------------------
  ERK1/2     PD98059     ↓ CSE induced MMP-1 (in vitro)                           [@b67-copd-1-137]
                         ↓ LPS-induced neutrophilia, cell death, airway leakage   [@b57-copd-1-137]
                         ↓ Airway epithelial thickening                           [@b88-copd-1-137]
             CI-1040     ↓ Adenoma proliferation ←→ Apoptosis                     [@b51-copd-1-137]
             UO126       ↓ Lung inflammation                                      [@b20-copd-1-137]
  p38        SB230580    ↓ LPS-induced MIP2, TNFα, neutrophilia                   Arcaroli et al 2004
             SB239063    ↓ LPS-induced IL-6 expression (in vitro)                 [@b95-copd-1-137]
                         ↓ LPS-induced fibrosis, MMP-9 expression, neutrophilia   [@b95-copd-1-137]
  SAPK/JNK   SP600125    ↓ Lung inflammation                                      [@b20-copd-1-137]
                         ↓ Arthritic joint swelling, collagenase expression       [@b38-copd-1-137]
             CEP-1347    ↓ Neuronal apoptosis                                     [@b65-copd-1-137]
                         ↓ Pancreatic edema, inflammation                         [@b98-copd-1-137]
